Literature DB >> 3619989

Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis.

A Sniderman, K Cianflone, P O Kwiterovich, T Hutchinson, P Barre, S Prichard.   

Abstract

In the present study, plasma cholesterol, triglyceride, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, and the major protein in LDL, apoB, were measured in 28 patients with chronic renal failure treated with hemodialysis and in 28 patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis (CAPD). Elevated plasma triglycerides and reduced HDL cholesterol were frequent in both the hemodialysis and CAPD patients. However LDL levels were significantly higher in the CAPD patients as evident both by LDL cholesterol and LDL apoB. Even so, only one of the CAPD patients was hypercholesterolemic whereas 14 (or 50%) had hyperapobetalipoproteinemia (HyperapoB). Insulin-dependent diabetes was more frequent in the CAPD group but only 2 of the 9 insulin-dependent diabetics in this group had HyperapoB, and therefore, diabetes mellitus cannot account for the difference between the 2 groups. Thus HyperapoB appears to be a prevalent dyslipoproteinemia in CAPD patients and as such might be another factor which places CAPD patients at particularly increased risk of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619989     DOI: 10.1016/0021-9150(87)90041-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

Review 1.  Cardiovascular risk in the peritoneal dialysis patient.

Authors:  Raymond T Krediet; Olga Balafa
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

2.  Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.

Authors:  X Yang; H Wang; Z Zhu; A Deng
Journal:  J Tongji Med Univ       Date:  1997

3.  Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.

Authors:  Philip K T Li; Bruce F Culleton; Amaury Ariza; Jun-Young Do; David W Johnson; Mauricio Sanabria; Ty R Shockley; Ken Story; Andrey Vatazin; Mauro Verrelli; Alex W Yu; Joanne M Bargman
Journal:  J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 10.121

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.